278 related articles for article (PubMed ID: 31427298)
21. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.
Johansen MD; Herrmann JL; Kremer L
Nat Rev Microbiol; 2020 Jul; 18(7):392-407. PubMed ID: 32086501
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases.
Huh HJ; Kim SY; Jhun BW; Shin SJ; Koh WJ
Infect Genet Evol; 2019 Aug; 72():169-182. PubMed ID: 30315892
[TBL] [Abstract][Full Text] [Related]
23.
Kaushik A; Ammerman NC; Martins O; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962331
[TBL] [Abstract][Full Text] [Related]
24. Genetic Correlation of Antibiotic Susceptibility and Resistance Genotyping for the
Zheng H; Liu D; Lu J; Song Y; Wang S; Zhao Y; Ni X
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397054
[TBL] [Abstract][Full Text] [Related]
25. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.
van Ingen J; Boeree MJ; van Soolingen D; Mouton JW
Drug Resist Updat; 2012 Jun; 15(3):149-61. PubMed ID: 22525524
[TBL] [Abstract][Full Text] [Related]
26. Identification and drug susceptibility testing for nontuberculous mycobacteria.
Huang WC; Yu MC; Huang YW
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S32-S41. PubMed ID: 32423573
[TBL] [Abstract][Full Text] [Related]
27. Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus.
Negatu DA; Beuchel A; Madani A; Alvarez N; Chen C; Aragaw WW; Zimmerman MD; Laleu B; Gengenbacher M; Dartois V; Imming P; Dick T
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0067621. PubMed ID: 34001512
[TBL] [Abstract][Full Text] [Related]
28.
Aragaw WW; Cotroneo N; Stokes S; Pucci M; Critchley I; Gengenbacher M; Dick T
Microbiol Spectr; 2022 Feb; 10(1):e0132121. PubMed ID: 35019671
[TBL] [Abstract][Full Text] [Related]
29. CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates.
Lee MR; Cheng A; Lee YC; Yang CY; Lai CC; Huang YT; Ho CC; Wang HC; Yu CJ; Hsueh PR
J Antimicrob Chemother; 2012 Jan; 67(1):222-5. PubMed ID: 21980068
[TBL] [Abstract][Full Text] [Related]
30. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
[TBL] [Abstract][Full Text] [Related]
31. A Screening of the MMV Pandemic Response Box Reveals Epetraborole as a New Potent Inhibitor against
Kim T; Hanh BT; Heo B; Quang N; Park Y; Shin J; Jeon S; Park JW; Samby K; Jang J
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073006
[No Abstract] [Full Text] [Related]
32. A review of current and promising nontuberculous mycobacteria antibiotics.
Cantelli CR; Dassonville-Klimpt A; Sonnet P
Future Med Chem; 2021 Aug; 13(16):1367-1395. PubMed ID: 34165325
[TBL] [Abstract][Full Text] [Related]
33. Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens.
Cho EH; Huh HJ; Song DJ; Lee SH; Kim CK; Shin SY; Ki CS; Jhun BW; Moon SM; Kwon OJ; Koh WJ; Lee NY
Diagn Microbiol Infect Dis; 2019 Feb; 93(2):107-111. PubMed ID: 30236529
[TBL] [Abstract][Full Text] [Related]
34. Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus.
Raynaud C; Daher W; Roquet-Banères F; Johansen MD; Stec J; Onajole OK; Ordway D; Kozikowski AP; Kremer L
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041716
[TBL] [Abstract][Full Text] [Related]
35. Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus.
Madani A; Negatu DA; El Marrouni A; Miller RR; Boyce CW; Murgolo N; Bungard CJ; Zimmerman MD; Dartois V; Gengenbacher M; Olsen DB; Dick T
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0066922. PubMed ID: 36005813
[TBL] [Abstract][Full Text] [Related]
36. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study.
Henriette Zweijpfenning SM; Chiron R; Essink S; Schildkraut J; Akkerman OW; Aliberti S; Altenburg J; Arets B; van Braeckel E; Delaere B; Gohy S; Haarman E; Lorent N; McKew G; Morgan L; Wagner D; van Ingen J; Hoefsloot W
Chest; 2022 Jul; 162(1):76-81. PubMed ID: 35063454
[No Abstract] [Full Text] [Related]
37. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease.
Choi H; Jhun BW; Kim SY; Kim DH; Lee H; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):293-295. PubMed ID: 29329759
[TBL] [Abstract][Full Text] [Related]
38. Disseminated Disease by Mycobacterium abscessus and Mycobacterium celatum in an Immunocompromised Host.
Locatelli ME; Tosto S; D'Agata V; Bonaventura P; Grasso RS; Marino A; Pampaloni A; Scuderi D; Cosentino F; Cacopardo B
Am J Case Rep; 2020 Apr; 21():e921517. PubMed ID: 32255770
[TBL] [Abstract][Full Text] [Related]
39. Thiostrepton: A Novel Therapeutic Drug Candidate for
Kim TH; Hanh BTB; Kim G; Lee DG; Park JW; Lee SE; Kim JS; Kim BS; Ryoo S; Jo EK; Jang J
Molecules; 2019 Dec; 24(24):. PubMed ID: 31835481
[No Abstract] [Full Text] [Related]
40. In vitro activity of tedizolid against the Mycobacterium abscessus complex.
Compain F; Soroka D; Heym B; Gaillard JL; Herrmann JL; Dorchène D; Arthur M; Dubée V
Diagn Microbiol Infect Dis; 2018 Mar; 90(3):186-189. PubMed ID: 29217419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
